Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Austerity Drama May Likely Spur The Pace But Not Change The Strategic Plot Line For Pharma

Executive Summary

Price cuts and austerity measures made 2011 a bleak year for European pharma. These dynamics are more severe but not new, and likely will accelerate firms’ existing geographic expansion and market access strategies.

You may also be interested in...



Europe For Pharma Mid-Caps: Tough But Necessary

Europe’s growing reimbursement hurdles and falling prices, compounded by a currency and sovereign debt crisis, mean the region’s no longer a strategic priority for Big Pharma. But while major pharmaceutical firms have sufficient scale and reach to continue to move jobs abroad and step up their emerging markets activities if conditions don’t improve closer to home, most of the rest of industry’s smaller commercial players – including the Big Biotechs – don’t.

Greece Austerity Hits Patented Drugs, But Generics May Be Slow To Profit

The Greek government passed a series of measures aimed at cutting spending on patented medicines, but generics may only take off slowly as the country favors domestic firms.

European Price Cuts, Restructuring Charges, Hit France's Ipsen in 2011

Ipsen's restructuring in France and the U.S, and European austerity measures, lead to a series of charges against 2011 profits, but drug sales increase 5% in the year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS053996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel